Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JPI-547 in Combination With mFOLFIRINOX or GemAbraxane in Advanced Pancreatic Cancer
NCT05257993Phase 2Recruiting
- Sponsor
- Onconic Therapeutics Inc.
- Start
- Mar 2022
- Primary completion
- Apr 2030
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of nesuparib in pancreatic ductal adenocarcinoma (PDAC), sponsored by Onconic Therapeutics Inc.. Started Mar 2022; status: recruiting.
02
Drugs
nesuparib
03
Conditions
pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT05257993.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05257993.